CanSino Biologics : Latest Study Shows Encouraging Results of CanSinoBIO’s mRNA COVID-19 Vaccine as Heterologous Booster
Tianjin, February [20]2023 – CanSino Biologics Inc. (“CanSinoBIO” or “the Company”) (SSE: 688185, HKEX: 06185) announced the recent release of Preprints with The Lancet, a collaboration between research exchange platform SSRN and The Lancet[1] the results of the Phase IIb study of CanSinoBIO’s mRNA COVID-19 vaccine (“CS-2034”). The results of the study showed that in adults 18 years and older who had previously received three doses of the inactivated drug, heterologous booster CS-2034 elicited higher immune responses and protection from the original SARS-CoV-2 and Omicron infections than those homologous booster Covid-19 vaccination.
The study was conducted during the recent outbreak in China, fueled by Omicron BA.5.2 and BF.7 subvariants. Real-world data showed that CS-2034 has a favorable safety profile and demonstrated efficacy, providing broader protection against COVID-19 infection than homologous inactivated boosters by inducing high-titre neutralizing antibodies against multiple SARS-CoV-2 strains become. The geometric mean titre (“GMT”) of neutralizing antibodies to BA.5 peaked at day 7 post-boost and represented on average 29-fold that induced by a homologous inactivated booster. Levels of neutralizing antibodies against BA.5 were 34.7 and 14.4 times those observed in the inactivated booster group on day 14 and day 28, respectively.
In addition, CS-2034 induced strong cellular immunity 7 days after inoculation, and the frequency of IFN-γ, IL-2, IL-5, and IL-13 positive T cells was significantly higher than those boosted with homologous inactivated vaccines.
CanSinoBIO’s mRNA technology platform is equipped with its proprietary sequence optimization software that can effectively identify key gene loci and improve antigen expression. As one of CanSinoBIO’s five core technology platforms, the company’s mRNA platform has significant advantages in R&D as it can be more easily adapted to new variants to shorten the production cycle, contributing to the scalability and faster commercialization of vaccine production. mRNA vaccines have significant potential in a variety of applications alongside COVID-19 vaccine, such as influenza vaccine, COVID+flu vaccine, and respiratory syncytial virus (“RSV”) vaccine.
Established in Shanghai in July 2021, CanSinoBIO’s mRNA facility has entered the trial production phase with a planned production capacity of 100 million doses per year. The company is currently preparing the phase III clinical trial for CS-2034.
[1]Source: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4356787
Disclaimer
Cansino Biologics Inc. posted this content on February 20, 2023 and is solely responsible for the information contained therein. Published by Public, unedited and unmodified, on 20 February 2023 02:29:04 UTC.